DuPont reports on early life nutrition studies

By Jim Cornall contact

- Last updated on GMT

DuPont has published an update to its work in the field of early life nutrition. Pic: DuPont
DuPont has published an update to its work in the field of early life nutrition. Pic: DuPont

Related tags: DuPont Nutrition & Biosciences, Dupont, HMO, Infant formula, early life nutrition

DuPont Nutrition & Biosciences recently released the findings of a study showing the effects Care4U 2’-FL had on dental caries-associated bacterium Streptococcus mutans.

Previously, HMOs have not been studied for their effects on oral bacteria, but as HMOs are increasingly being added to infant formula, the company said it is important to evaluate effects on oral microflora and potential impact on oral health.

“Human milk is known to contain factors that protect against caries, so we were interested to know how HMOs, and especially 2’-FL, affect S. mutans, one of the most studied bacteria related to dental caries,”​ said Johanna Hirvonen Ph.D., senior scientist, DuPont Nutrition & Biosciences.

This study was a collaboration between University of Turku, Institute of Dentistry and DuPont Nutrition & Biosciences. We evaluated the ability of S. mutans to grow on 2’-fucosyllactose (2’-FL) in comparison to galacto-oligosaccharides (GOS), lactose, and xylitol. The effects of 2’-FL, GOS, lactose, and xylitol on adhesion properties of S. mutans were also evaluated. While this study was done under in vitro conditions, it showed the differences between the studied carbohydrates, especially in S. mutans growth.”

Krista Salli, scientist at DuPont Nutrition & Biosciences, said, “Though it is known that S. mutans can metabolize many carbon sources, we found that S. mutans was unable to grow on 2’-FL, while it grew well on GOS and lactose. Xylitol, as known before, reduced the growth of S. mutans,” added Krista Salli, M.Sc., Scientist, DuPont Nutrition & Biosciences. “Thus, the data suggests that addition of 2’-FL to infant formula would not support the growth of S. mutans.  The results highlight the selectivity of 2’-FL consumption by oral bacteria.”

Adhesion to tooth surfaces is the first requirement for a biofilm—dental plaque–formation, and 2’-FL decreased the adhesive properties of some of the studied S. mutans​ strains. In infancy, oral microbiota develops, and delays colonization of potentially pathogenic bacteria is vital. DuPont is expanding on this line of research with other oral bacteria and additional HMOs.

DOI: https://doi.org/10.1017/S0007114520001956 

New HMO, 3-FL

In addition to the research being conducted on Care4U 2’-FL, DuPont said it recognizes the need to continue to bridge the nutritional gap in infant formula.

The next most abundant HMO in human milk after 2’-FL, and soon to be commercialized by DuPont, is 3-fucosyllactose (3-FL). This HMO is present in human milk of all mothers and is unique in that levels have been reported to increase during lactation, contrary to 2’FL that decreases during lactation. Initial in vitro​ research demonstrates that in addition to being bifidogenic, this HMO is effective in reducing colon motor contractions and inhibits bacterial adhesion. Further research is needed to confirm clinical benefits.

A scientific expert panel has recently concluded that DuPont’s newest HMO, Care4U 3-FL HMO, is Generally Recognized as Safe (GRAS) for use in various applications including formulas intended for infants and young children, other foods and beverages consumed by toddlers under three years of age, as well as foods for the general population.

The FDA has been notified of DuPont’s GRAS conclusion.

In October 2019, DuPont submitted a novel food application with the European Food Safety Authority (EFSA) to obtain market authorization in the EU for 3-FL. These regulatory developments demonstrate the steady progression of DuPont’s investment and commitment to HMOs.

New applications

Recent published research by DuPont has also demonstrated a high-performance liquid chromatography (HPLC) method is available that allows researchers and formulators to analyze the amount of 2’-FL and 3-FL in a range of food products and perform shelf-life studies in these food applications.

The company said this is a major step forward for manufacturers interested in to developing high quality, efficacious nutritional products for early life nutrition and beyond.

“At DuPont, we’re excited to continue our innovation in Early Life Nutrition with HMOs and probiotics to support healthy growth and development during infancy,”​ said Ratna Mukherjea, Ph.D., technical fellow and global research and development leader, Human Milk Oligosaccharides, DuPont Nutrition & Biosciences.

“Further, the health benefits of HMOs and probiotics can be extended beyond infant nutrition to that of adult nutrition and dietary supplements.”

 

Related news

Show more

comments

Post your comment

We will not publish your email address on the website

These comments have not been moderated. You are encouraged to participate with comments that are relevant to our news stories. You should not post comments that are abusive, threatening, defamatory, misleading or invasive of privacy. For the full terms and conditions for commenting see clause 7 of our Terms and Conditions ‘Participating in Online Communities’. These terms may be updated from time to time, so please read them before posting a comment. Any comment that violates these terms may be removed in its entirety as we do not edit comments. If you wish to complain about a comment please use the "REPORT ABUSE" button or contact the editors.

Follow us

Products

View more

Webinars